HealthCare Global Enterprises (HCG) announced a research collaboration with Trucan Diagnostics, a startup specialising in advanced cancer diagnostics. This partnership aims to validate a suite of novel diagnostic tests designed to improve the detection of primary and recurrent/metastatic cancer precisely, predict therapy responses, and monitor treatment efficacy.
Under this partnership, HCG and Trucan will work together to conduct extensive validation studies on a new set of cancer diagnostic tests developed by Trucan. These tests employ advanced techniques, including next-generation sequencing and novel biomarker-driven diagnostics, to enable precise primary, recurrent/metastatic cancer detection, pre-treatment prediction of response to therapy and monitoring patients undergoing chemo or targeted therapy. The results of these studies aim to generate the necessary data to assess and confirm the clinical utility of these tests, paving the way for their potential integration into routine clinical practice.
The novel biomarker-driven cancer detection methods developed by Trucan aim to improve over current method aiding oncologists to personalise treatment plans and minimise ineffective therapies and associated morbidity while reducing overall treatment costs.